HHS cost-effectiveness research conference set for Nov. 25-26 to review panel report.
This article was originally published in The Gray Sheet
Executive Summary
HHS COST-EFFECTIVENESS RESEARCH WORKSHOP TO BE CONVENED NOV. 25-26 to explore the implications of a new report developed by the Panel on Cost-Effectiveness in Health and Medicine. Sponsored by several PHS agencies and the Health Care Financing Administration, the workshop will be held on the campus of the National Institutes of Health in Bethesda, Maryland.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.